LOX-1 mediated phenotypic switching of pulmonary arterial smooth muscle cells contributes to hypoxic pulmonary hypertension

W Zhang, T Zhu, W Wu, X Ge, X Xiong, Z Zhang… - European journal of …, 2018 - Elsevier
W Zhang, T Zhu, W Wu, X Ge, X Xiong, Z Zhang, C Hu
European journal of pharmacology, 2018Elsevier
In pulmonary hypertension (PH), pulmonary arterial smooth muscle cells (PASMCs) are
dedifferentiated, undergoing a contractile-to-synthetic phenotypic switching. Lectin-like
oxidized low-density lipoprotein receptor-1 (LOX-1) plays diverse roles in the cardiovascular
system, but its contribution to PH remains to be fully defined. The present study was
undertaken to explore the role of LOX-1 in PASMCs dedifferentiation in hypoxia-induced
pulmonary vascular remodeling and PH. In a rat model of hypoxic PH, pulmonary vascular …
Abstract
In pulmonary hypertension (PH), pulmonary arterial smooth muscle cells (PASMCs) are dedifferentiated, undergoing a contractile-to-synthetic phenotypic switching. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) plays diverse roles in the cardiovascular system, but its contribution to PH remains to be fully defined. The present study was undertaken to explore the role of LOX-1 in PASMCs dedifferentiation in hypoxia-induced pulmonary vascular remodeling and PH. In a rat model of hypoxic PH, pulmonary vascular remodeling was accompanied by increased expression of LOX-1 in pulmonary arteries. In primary rat PASMCs, hypoxia-induced PASMCs dedifferentiation occurred concomitantly with LOX-1 upregulation. Inhibition of LOX-1 by either siRNA knockdown or neutralizing antibody significantly ameliorated PASMCs dedifferentiation. Mechanistically, LOX-1 promotes PASMCs dedifferentiation under hypoxic conditions via ERK1/2-Elk-1/MRTF-A/SRF signaling pathway. In conclusion, our data uncovers an important role of LOX-1 in the maintenance of PASMCs phenotype. Therapeutic targeting of LOX-1/ERK1/2-Elk-1/MRTF-A/SRF signaling axis would be exploited to treat hypoxic PH.
Elsevier